Research Topic: Medicinal

Comparative Analysis of Main Agronomic Traits of Different Pleurotus giganteus Germplasm Resources

Scientists studied 15 different varieties of giant oyster mushrooms to understand their growth characteristics and quality traits. They tested how fast the mushroom threads grow at different temperatures, measured the size and weight of the mushrooms produced, and calculated how efficiently each variety converts growing material into edible mushrooms. Strain No. 9 performed best with the largest yields and highest quality mushrooms, while different strains showed distinct characteristics that could be used to develop superior commercial varieties.

Read More »

Single-dose psilocybin alters resting state functional networks in patients with body dysmorphic disorder

Researchers gave eight patients with body dysmorphic disorder (an excessive preoccupation with appearance flaws) a single dose of psilocybin and measured their brain activity before and after treatment. They found that psilocybin increased communication between key brain regions involved in decision-making and attention control. Patients whose brains showed these changes experienced significant symptom improvement within a week, suggesting psilocybin may help by enhancing mental flexibility and emotional regulation in BDD.

Read More »

Pleurotus spp.—an effective way in degradation mycotoxins? A comprehensive review

This review examines how oyster mushrooms (Pleurotus species) can break down mycotoxins—harmful compounds produced by molds in food and animal feed. These mushrooms produce special enzymes that can degrade toxins like aflatoxins and zearalenone, potentially reaching 30-100% degradation depending on conditions. This offers a safer, more environmentally friendly alternative to chemical detoxification methods currently used in the food industry.

Read More »

Psilocybin, an Effective Treatment for Major Depressive Disorder in Adults – A Systematic Review

Psilocybin, a naturally occurring compound found in certain mushroom species, shows significant promise as a treatment for depression. Clinical studies reviewed in this research found that psilocybin-assisted therapy reduced depressive symptoms in every patient studied, with improvements lasting months after treatment. Unlike traditional antidepressants, psilocybin caused only mild temporary side effects and worked faster, suggesting it could become an important alternative treatment for depression.

Read More »

Advanced Fungal Biotechnologies in Accomplishing Sustainable Development Goals (SDGs): What Do We Know and What Comes Next?

Fungi are remarkable organisms with tremendous untapped potential for solving global challenges. They can be engineered to produce life-saving medicines like antibiotics and cholesterol-lowering drugs, create nutritious food alternatives, clean up polluted environments, and help fight climate change. As we transition to more sustainable living practices, fungi represent a natural solution that has been used for centuries but is only now being fully appreciated through modern biotechnology.

Read More »

Harnessing the yeast Saccharomyces cerevisiae for the production of fungal secondary metabolites

Scientists have learned to use common baker’s yeast (S. cerevisiae) as a biological factory to produce valuable medicines and compounds that naturally come from fungi and mushrooms. By transferring the genetic instructions for making these compounds into yeast cells and improving them with genetic engineering, researchers can now produce therapeutically important substances like cancer-fighting drugs and antibiotics in large quantities. This approach is more practical and cost-effective than trying to extract these rare compounds directly from their native fungal sources or using other production methods.

Read More »

Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program

Switzerland operates a unique program allowing controlled use of psychedelics (LSD, psilocybin) and MDMA to help patients with serious mental health conditions that haven’t responded to standard treatments. Since 2014, about 100 doctors have treated 700+ patients with these substances as part of therapy sessions. The program requires careful patient screening, informed consent, and outcome reporting, with patients typically receiving 2-4 treatments over 12 months. Most patients showed significant improvement in their conditions, though some experienced side effects like nausea or headaches.

Read More »

Anti-Inflammatory Effects of Solanum tuberosum L. Polysaccharide and Its Limited Gene Expression Profile

Researchers studied a natural compound from potatoes called STP that reduces inflammation in the body. Using laboratory cells and animal models, they found that STP works similarly to the common pain reliever ibuprofen by reducing inflammatory chemicals and activating the body’s protective defense systems. This discovery suggests that potato-based polysaccharides could be developed into new treatments for inflammatory diseases and conditions related to oxidative stress.

Read More »

Why psychedelic-assisted therapy studies in eating disorders risk missing the mark on outcomes: a phenomenological psychopathology perspective

This scientific commentary examines how research on psychedelic-assisted therapy for eating disorders may be missing important aspects of how people actually experience the treatment. The authors argue that current study methods rely too heavily on questionnaires that don’t capture the full depth of what people experience during psychedelic sessions. They propose using phenomenological approaches—methods that deeply explore lived experience—to better understand which aspects of the psychedelic experience actually lead to recovery from eating disorders.

Read More »
Scroll to Top